Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SNSE | Common Stock | Purchase | $3.85K | +1.2K | +0.02% | $3.20 | 5.23M | Mar 2, 2022 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | This Form 4/A is being filed solely to correct the number of shares beneficially owned following the transaction reported herein. |
F2 | These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares. |